Evidence map›Paper›PMID 39070044›Full record

ArticleOpen forum infectious diseases2024

Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls.

Myrthe L Verburgh, Anders Boyd, Maarten F Schim van der Loeff, Margreet Bakker, Ferdinand W N M Wit, Marc van der Valk, Marloes Grobben, Lisa van Pul, Khadija Tejjani, Jacqueline van Rijswijk and 5 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Myrthe L VerburghAmsterdam University Medical Centers, University of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-8747-0395
Anders BoydAmsterdam University Medical Centers, University of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands.
Maarten F Schim van der LoeffAmsterdam University Medical Centers, University of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands.
Margreet BakkerAmsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
Ferdinand W N M WitAmsterdam University Medical Centers, University of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands.
Marc van der ValkAmsterdam University Medical Centers, University of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands.
Marloes GrobbenAmsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
Lisa van PulAmsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
Khadija TejjaniAmsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
Jacqueline van RijswijkAmsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
Marit J van GilsAmsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
Neeltje A KootstraAmsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
Lia van der HoekAmsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-2803-642X
Peter ReissAmsterdam University Medical Centers, University of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands.
AGEhIV Cohort Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Little is known about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection in people with human immunodeficiency virus (HIV; PWH) with vaccine-induced or hybrid immunity. We assessed the incidence of Omicron infection in 209 AGE Methods: From September 2020 onward, participants were assessed every 6 months for the incidence of SARS-CoV-2 infection, per SARS-CoV-2 nucleocapsid antibody assay or self-reported positive antigen or polymerase chain reaction test. Between 1 January and 31 October 2022, the cumulative incidence of Omicron infection and associated risk factors were estimated using a conditional risk-set Cox proportional hazards model. Results: The cumulative incidence of a first Omicron infection was 58.3% by 31 October 2022, not significantly different between groups. HIV status was not independently associated with acquiring Omicron infection. Former and current smoking, as well as an increased predicted anti-spike immunoglobulin G titer were significantly associated with a lower risk of Omicron infection. The majority of infections were symptomatic, but none required hospitalization. Conclusions: People with well-controlled HIV and controls in our cohort experienced a similarly high proportion of Omicron infections. More booster vaccinations significantly reduced the risk of infection.

Indexed as

HIVincidenceOmicron variantSARS-CoV-2serology

Identifiers

PMID39070044
PMCPMC11273239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.